Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Current Deferred Revenue (2016 - 2026)

Veracyte's Current Deferred Revenue history spans 12 years, with the latest figure at $1.2 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 30.66% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 30.66% decrease, with the full-year FY2025 number at $1.2 million, down 30.66% from a year prior.
  • Current Deferred Revenue hit $1.2 million in Q4 2025 for Veracyte, up from $417000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for VCYT hit a ceiling of $4.9 million in Q1 2022 and a floor of $417000.0 in Q3 2025.
  • Historically, Current Deferred Revenue has averaged $2.3 million across 5 years, with a median of $2.2 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: soared 1152.29% in 2021 and later crashed 79.49% in 2025.
  • Tracing VCYT's Current Deferred Revenue over 5 years: stood at $4.6 million in 2021, then tumbled by 43.76% to $2.6 million in 2022, then dropped by 23.15% to $2.0 million in 2023, then fell by 16.68% to $1.7 million in 2024, then crashed by 30.66% to $1.2 million in 2025.
  • Business Quant data shows Current Deferred Revenue for VCYT at $1.2 million in Q4 2025, $417000.0 in Q3 2025, and $1.4 million in Q2 2025.